399 related articles for article (PubMed ID: 16364833)
1. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
Daull P; Benrezzak O; Arsenault D; Pheng LH; Blouin A; Cayer J; Beaudoin M; Belleville K; Sirois P; Nantel F; Jeng AY; Battistini B
Am J Hypertens; 2005 Dec; 18(12 Pt 1):1606-13. PubMed ID: 16364833
[TBL] [Abstract][Full Text] [Related]
2. Triple vasopeptidase inhibition of angiotensin-converting enzyme/neutral endopeptidase/endothelin-converting enzyme activities on the hemodynamic profile of chronically instrumented unrestrained conscious spontaneously hypertensive rats.
Daull P; Blouin A; Sirois P; Nantel F; Jeng AY; Battistini B
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S398-401. PubMed ID: 15838331
[TBL] [Abstract][Full Text] [Related]
3. CGS 35601, a triple inhibitor of angiotensin converting enzyme, neutral endopeptidase and endothelin converting enzyme.
Battistini B; Daull P; Jeng AY
Cardiovasc Drug Rev; 2005; 23(4):317-30. PubMed ID: 16614731
[TBL] [Abstract][Full Text] [Related]
4. The first preclinical pharmacotoxicological safety assessment of CGS 35601, a triple vasopeptidase inhibitor, in chronically instrumented, conscious, and unrestrained spontaneously hypertensive rats.
Daull P; Lepage R; Benrezzak O; Cayer J; Beaudoin M; Belleville K; Blouin A; Sirois P; Nantel F; Jeng AY; Battistini B
Drug Chem Toxicol; 2006; 29(2):183-202. PubMed ID: 16707327
[TBL] [Abstract][Full Text] [Related]
5. Combined inhibition of neutral endopeptidase with angiotensin converting enzyme or endothelin converting enzyme in experimental diabetes.
Tikkanen I; Tikkanen T; Cao Z; Allen TJ; Davis BJ; Lassila M; Casley D; Johnston CI; Burrell LM; Cooper ME
J Hypertens; 2002 Apr; 20(4):707-14. PubMed ID: 11910307
[TBL] [Abstract][Full Text] [Related]
6. Effects of the ECE/NEP inhibitor CGS 34225 on the big ET-1-induced pressor response and plasma atrial natriuretic peptide concentration in conscious rats.
Trapani AJ; Beil ME; Bruseo CW; Fink CA; Hoyer D; Savage P; Jeng AY
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():102S-106S. PubMed ID: 12193065
[TBL] [Abstract][Full Text] [Related]
7. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats.
Emoto N; Raharjo SB; Isaka D; Masuda S; Adiarto S; Jeng AY; Yokoyama M
Hypertension; 2005 Jun; 45(6):1145-52. PubMed ID: 15897363
[TBL] [Abstract][Full Text] [Related]
8. CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
Trapani AJ; Beil ME; Bruseo CW; Savage P; Firooznia F; Jeng AY
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S211-5. PubMed ID: 15838282
[TBL] [Abstract][Full Text] [Related]
9. Effects of benazepril, an angiotensin-converting enzyme inhibitor, combined with CGS 35066, a selective endothelin-converting enzyme inhibitor, on arterial blood pressure in normotensive and spontaneously hypertensive rats.
Battistini B; Ayach B; Molez S; Blouin A; Jeng AY
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():363S-366S. PubMed ID: 12193123
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological properties of CGS 35066, a potent and selective endothelin-converting enzyme inhibitor, in conscious rats.
Trapani AJ; Beil ME; Bruseo CW; De Lombaert S; Jeng AY
J Cardiovasc Pharmacol; 2000 Nov; 36(5 Suppl 1):S40-3. PubMed ID: 11078331
[TBL] [Abstract][Full Text] [Related]
11. The hemodynamic and metabolic profiles of Zucker diabetic fatty rats treated with a single molecule triple vasopeptidase inhibitor, CGS 35601.
Daull P; Blouin A; Beaudoin M; Gadbois S; Belleville K; Cayer J; Berthiaume N; Sirois P; Nantel F; Jeng AY; Battistini B
Exp Biol Med (Maywood); 2006 Jun; 231(6):824-9. PubMed ID: 16741006
[TBL] [Abstract][Full Text] [Related]
12. Triple VPI CGS 35601 reduces high blood pressure in low-renin, high-salt Dahl salt-sensitive rats.
Daull P; Blouin A; Belleville K; Beaudoin M; Arsenault D; Leonard H; Sirois P; Nantel F; Jeng AY; Battistini B
Exp Biol Med (Maywood); 2006 Jun; 231(6):830-3. PubMed ID: 16741007
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of a non-peptidic dual inhibitor of neutral endopeptidase 24.11 and endothelin-converting enzyme.
De Lombaert S; Ghai RD; Jeng AY; Trapani AJ; Webb RL
Biochem Biophys Res Commun; 1994 Oct; 204(1):407-12. PubMed ID: 7945387
[TBL] [Abstract][Full Text] [Related]
14. Benzofused macrocyclic lactams as triple inhibitors of endothelin-converting enzyme, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
Ksander GM; Savage P; Trapani AJ; Balwierczak JL; Jeng AY
J Cardiovasc Pharmacol; 1998; 31 Suppl 1():S71-3. PubMed ID: 9595404
[TBL] [Abstract][Full Text] [Related]
15. CGS 34043: a non-peptidic, potent and long-acting dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
Trapani AJ; De Lombaert S; Beil ME; Bruseo CW; Savage P; Chou M; Jeng AY
Life Sci; 2000; 67(9):1025-33. PubMed ID: 10954036
[TBL] [Abstract][Full Text] [Related]
16. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases.
Daull P; Jeng AY; Battistini B
J Cardiovasc Pharmacol; 2007 Sep; 50(3):247-56. PubMed ID: 17878751
[TBL] [Abstract][Full Text] [Related]
17. Protective effects of a dual endothelin converting enzyme/neutral endopeptidase inhibitor on the development of pulmonary hypertension secondary to cardiac dysfunction in the rat.
Dai ZK; Hsieh CC; Chai CY; Wu JR; Jeng AY; Chou SH; Wu BN; Yeh JL; Chen IJ; Tan MS
Pediatr Pulmonol; 2010 Nov; 45(11):1076-85. PubMed ID: 20658482
[TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase in rats with hypertension.
French JF; Anderson BA; Downs TR; Dage RC
J Cardiovasc Pharmacol; 1995 Jul; 26(1):107-13. PubMed ID: 7564349
[TBL] [Abstract][Full Text] [Related]
19. CGS 34226, a thiol-based dual inhibitor of endothelin converting enzyme-1 and neutral endopeptidase 24.11.
Jeng AY; Savage P; Beil ME; Bruseo CW; Hoyer D; Fink CA; Trapani AJ
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():98S-101S. PubMed ID: 12193064
[TBL] [Abstract][Full Text] [Related]
20. The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans.
Seed A; Kuc RE; Maguire JJ; Hillier C; Johnston F; Essers H; de Voogd HJ; McMurray J; Davenport AP
Life Sci; 2012 Oct; 91(13-14):743-8. PubMed ID: 22480515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
